Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 6/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 5/20 | 0.47 |
| ▸ | TAS1R2 | Q8TE23 | 5/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4090084 | 0.99 | ALDH1A1 (0.47) | TAS1R3TAS1R1TAS1R2ALDH1A1KDM4E | |
| SCHEMBL4091305 | 0.96 | ALDH1A1 (0.47) | TAS1R3TAS1R1TAS1R2ALDH1A1KDM4E | |
| SCHEMBL4084014 | 0.94 | ALDH1A1 (0.46) | TAS1R3TAS1R1TAS1R2ALDH1A1KDM4E | |
| SCHEMBL4080979 | 0.79 | ALDH1A1 (0.60) | ALDH1A1KDM4EMAPTHPGDL3MBTL1 | |
| SCHEMBL4084751 | 0.77 | CNR2 (0.58) | ALDH1A1KDM4EMAPTHPGDABCC1 | |
| SCHEMBL3745498 | 0.77 | ABCC1 (0.51) | ALDH1A1KDM4EMAPTHPGDL3MBTL1 | |
| SCHEMBL4080989 | 0.76 | CNR2 (0.46) | ALDH1A1KDM4EMAPTHPGDLMNA | |
| SCHEMBL4091485 | 0.76 | ALDH1A1 (0.49) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 | |
| SCHEMBL4091316 | 0.76 | ALDH1A1 (0.58) | ALDH1A1KDM4EMAPTHPGDL3MBTL1 | |
| SCHEMBL4085526 | 0.75 | CNR2 (0.47) | ALDH1A1KDM4EMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338623-B2 | N-{3-[(2,5-dimethylmorpholin-4-yl)carbonyl]-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl}hexahydro-2,5-methanopentalene-3a(1H)-carboxamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBVIE INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20090018114-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018114-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | TAS1R3 539/4885TAS1R1 501/4885TAS1R2 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.